Keyphrases
Hemophilia
94%
Emicizumab
69%
Pediatric
62%
Thrombin Generation
59%
Pediatric Patients
39%
Bleeding
30%
Hemostasis
30%
Pediatric Population
24%
Rare Bleeding Disorders
23%
Thrombosis
22%
Recombinant Activated Factor VII (rFVIIa)
21%
Venous Thromboembolism
21%
Glanzmann Thrombasthenia
21%
Hematological Malignancies
21%
Severe Haemophilia A
20%
Neonatal Alloimmune Thrombocytopenia
20%
Neonate
18%
FVIII Inhibitors
17%
Risk Factors
17%
Acute Lymphoblastic Leukemia
16%
Hemophilia B
16%
Bleeding Complications
16%
Factor VIII (FVIII)
16%
Bleeding Episodes
16%
Thrombosis Risk
16%
Treatment Options
15%
Cancer-associated Thrombosis
15%
Etiology
15%
Thromboembolism
15%
Hemostatic System
15%
Bleeding Disorders
13%
Anticoagulant Treatment
13%
Thrombophilia
13%
Children with Cancer
13%
Factor XI Deficiency
13%
Hemophilia A Carrier
13%
Age-related
13%
Single-center Experience
13%
Inherited Thrombophilia
13%
Surgical Procedures
13%
Laboratory Assays
13%
Bleeding Tendency
13%
Thrombotic Complications
12%
Platelets
12%
Epidemiology
12%
Thrombocytopenia
12%
Central Venous Line
12%
Von Willebrand Disease
11%
Etiological Factors
11%
FEIBA
11%
Medicine and Dentistry
Haemophilia A
100%
Pediatrics
79%
Emicizumab
56%
Bleeding
55%
Thrombin
49%
Hemostat
40%
Thrombosis
37%
Bleeding Disorder
36%
Pediatrics Patient
32%
Patient with Hemophilia
31%
Diseases
30%
Blood Stasis
29%
Malignant Neoplasm
23%
Glanzmann's Thrombasthenia
21%
Neonatal Alloimmune Thrombocytopenia
20%
Hematologic Malignancy
18%
Haemophilia B
17%
Acute Lymphoblastic Leukemia
16%
Substitution Therapy
15%
Activated Prothrombin Complex
15%
Thrombophilia
15%
Neonate
15%
Anticoagulant Therapy
14%
Prospective Study
14%
Ex Vivo
14%
Ciclonicate
14%
Venous Thromboembolism
13%
Immunological Tolerance
13%
Thrombocytopenia
13%
Factor XI
13%
Phlebothrombosis
13%
Mucormycosis
13%
Bleeding Diathesis
13%
Surgical Technique
12%
Platelet
10%
Retrospective Study
10%
Blood Clotting Factor 8 Inhibitor
9%
Thromboembolism
9%
Cancer
9%
Invasive Procedure
9%
Pediatric Hematology
8%
Blood Clotting Factor
8%
Delayed Diagnosis
8%
Thrombotic Thrombocytopenic Purpura
8%
Adverse Event
8%
Cohort Effect
7%
Central Venous Catheter
7%
Thromboelastography
7%
Blood Clotting Factor 8
7%
Cerebral Hemorrhage
7%
